Obesity (Disorder), Overweight , Obesity
Conditions
Keywords
Obesity, Weightloss, Tirzepatide, Adults, Body composition, Dose escalation
Brief summary
Tirzepatide is one of the new medications for the treatment of obesity. In clinical research people treated with Tirzepatide have weight loss up to 21%. But there is only a little bit of research showing the effect of Tirzepatide in clinical practice. In this retrospective observational study the investigators will evaluate the effectiveness of tirzepatide in routine clinical practice among adults with obesity in the Netherlands.The main questions it aims to answer are: * How much weight do patients lose after six months of treatment with tirzepatide combined with lifestyle coaching? * How is the medication dosed in daily practice? Researchers will use data from electronic health records of patients in multiple outpatient locations of the Dutch Obesity Clinic (NOK, Nederlandse Obesitas Kliniek).
Interventions
DRUGTirzepatide
Initiating treatment with tirzepatide
Sponsors
Radboud University Medical Center
Nederlandse Obesitas Kliniek
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults (age ≥18 years old) * A BMI of ≥ 30 kg/m2 or a BMI ≥ 27 kg/m2 with at least one obesity complication (e.g., hypertension, dyslipidaemia)
Exclusion criteria
* Pregnant women or pregnancy during treatment * Previously treated for obesity (with pharmacotherapy, endoscopic treatment or metabolic-bariatric surgery) * Patients with diabetes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Weight change | Baseline-6 months | %TWL= (start weight - 6 month weight/baseline weight)\*100% |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in body composition | Basline-6 months | Fat percentage (FP) and fat free mass (FFM) |
| Demographic and clinical characteristics | Baseline | * Age * Gender * Treatment location * Obesity associated diseases: hypertension, dyslipidaemia, sleep apnoea and osteoarthritis * Previous lifestyle treatment for obesity |
| Weight loss by maintenance dose | Baseline-6 months | Maintenance dose (10mg and 15mg) |
| Tirzepatide dosing patterns | Baseline-6 months | Including the initial prescribed dose and subsequent dose escalations throughout the treatment course |
| Weigth | Baseline-6 months | in kilograms (kg) |
| Height | Baseline-6 months | in centimeters (cm) |
Countries
Netherlands
Contacts
CONTACTPuck van den Hooff, MD
CONTACTValerie Monpellier, MD, PhD
PRINCIPAL_INVESTIGATORMaria Hopman, MD, PhD
Radboud University Medical Center
Outcome results
None listed